VIVUS (VVUS) : Meditor Group Ltd reduced its stake in VIVUS by 38.29% during the most recent quarter end. The investment management company now holds a total of 1,830,000 shares of VIVUS which is valued at $3,294,000 after selling 1,135,616 shares in VIVUS , the firm said in a disclosure report filed with the SEC on Apr 18, 2016.VIVUS makes up approximately 2.28% of Meditor Group Ltd’s portfolio.
VIVUS opened for trading at $1.78 and hit $1.82 on the upside on Friday, eventually ending the session at $1.8, with a gain of 0.56% or 0.01 points. The heightened volatility saw the trading volume jump to 5,79,812 shares. Company has a market cap of $187 M.
Other Hedge Funds, Including , Simplex Trading sold out all of its stake in VVUS during the most recent quarter. The investment firm sold 18,606 shares of VVUS which is valued $32,002.Creative Planning reduced its stake in VVUS by selling 6,982 shares or 45.52% in the most recent quarter. The Hedge Fund company now holds 8,355 shares of VVUS which is valued at $14,371.
On the company’s financial health, VIVUS reported $-0.12 EPS for the quarter, based on the information available during the earnings call on Mar 9, 2016. Analyst had a consensus estimate of $-0.12. The company had revenue of $15.34 million for the quarter, compared to analysts expectations of $22.90 million. The company’s revenue was down -29.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.25 EPS.
VIVUS Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA) which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC) under the name SPEDRA for the treatment of ED in the Europe. As of September 18 2014 the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.